A novel, safe and resistance-free treatment of vaginal candida infections
| Reference number | |
| Coordinator | GEDEA BIOTECH AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | April 2017 - September 2017 |
| Status | Completed |
| Venture | Innovative Startups |
Important results from the project
The purpose of the project has been fulfilled, as we have verified that a vaginal tablet with slow release of the substance GA101 can be produced with a low cost per tablet. The final tablet composition has been selected and we can thus make a cost and time assessment for the continued formulation development up to clinical trials.
Expected long term effects
The aim of the project was to produce vaginal tablet prototypes to verify that a vaginal tablet that meets the requirements for release rate of substance, pH, and users´ wishes, can be manufactured. The prototype production has verified that we can produce a vaginal tablet with the desired properties and decision on the final tablet composition has been made for further formulation development.
Approach and implementation
A number of prototypes of vaginal tablets with our substance GA101 have been manufactured and an in vitro release model has been developed. The prototypes have been analyzed for release rate and pH in collaboration with Galenica AB, which are experts in drug formulation. Based on the results, a formulation with desirable properties has been chosen for continued formulation development.